Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

YOHIMBINE HYDROCHLORIDE CRS (25 MG)

YOHIMBINE HYDROCHLORIDE CRS (25 MG)

65-19-0

DISCOVER
IOTROLAN FOR SYSTEM SUITABILITY CRS (5 MG)

IOTROLAN FOR SYSTEM SUITABILITY CRS (5 MG)

79770-24-4

DISCOVER
PYRROLIDONE CRS (20 MG)

PYRROLIDONE CRS (20 MG)

616-45-5

DISCOVER
FEBANTEL FOR SYSTEM SUITABILITY CRS (10 MG)

FEBANTEL FOR SYSTEM SUITABILITY CRS (10 MG)

58306-30-2

DISCOVER
VERBENALIN CRS (11 MG)

VERBENALIN CRS (11 MG)

548-37-8

DISCOVER
RIBONUCLEIC ACID CRS (100 MG)

RIBONUCLEIC ACID CRS (100 MG)

63231-63-0

DISCOVER
METHOTREXATE IMPURITY C CRS (10 MG)

METHOTREXATE IMPURITY C CRS (10 MG)

NA

DISCOVER
METHOTREXATE IMPURITY E CRS (10 MG)

METHOTREXATE IMPURITY E CRS (10 MG)

NA

DISCOVER
TERAZOSIN IMPURITY E CRS (10 MG)

TERAZOSIN IMPURITY E CRS (10 MG)

NA

DISCOVER
Terazosin for system suitability CRS, 0.59mg

Terazosin for system suitability CRS, 0.59mg

70024-40-7

DISCOVER
HUMAN COAGULATION FACTOR VII CONCENTRATE  BRP (25 MG)

HUMAN COAGULATION FACTOR VII CONCENTRATE BRP (25 MG)

9001-25-6

DISCOVER
TIBOLONE FOR SYSTEM SUITABILITY CRS (10 MG)

TIBOLONE FOR SYSTEM SUITABILITY CRS (10 MG)

5630-53-5

DISCOVER